These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2040 related articles for article (PubMed ID: 31471138)

  • 1. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.
    Yu YD; Kim TJ
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
    Hillerdal V; Essand M
    BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies.
    Porter LH; Harrison SG; Risbridger GP; Lister N; Taylor RA
    J Steroid Biochem Mol Biol; 2024 Oct; 243():106571. PubMed ID: 38909866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.
    Soltantoyeh T; Akbari B; Karimi A; Mahmoodi Chalbatani G; Ghahri-Saremi N; Hadjati J; Hamblin MR; Mirzaei HR
    Cells; 2021 Jun; 10(6):. PubMed ID: 34207884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T cell therapy: a potential new strategy against prostate cancer.
    Schepisi G; Cursano MC; Casadei C; Menna C; Altavilla A; Lolli C; Cerchione C; Paganelli G; Santini D; Tonini G; Martinelli G; De Giorgi U
    J Immunother Cancer; 2019 Oct; 7(1):258. PubMed ID: 31619289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
    Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects and challenges for use of CAR T cell therapies in solid tumors.
    Ramakrishna S; Barsan V; Mackall C
    Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
    [No Abstract]   [Full Text] [Related]  

  • 15. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
    Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
    Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
    Weimin S; Abula A; Qianghong D; Wenguang W
    Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
    [No Abstract]   [Full Text] [Related]  

  • 20. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.
    Grywalska E; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Niedźwiedzka-Rystwej P; Roliński J
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 102.